| Old Articles: <Older 6111-6120 Newer> |
|---|
 |
The Motley Fool
January 5, 2010
Brian Orelli |
Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out.   |
The Motley Fool
January 4, 2010
Brian Orelli |
You Don't Need Your Contacts In to See This Deal Novartis acts first to grab the rest of Nestle's stake in Alcon. |
The Motley Fool
December 31, 2009
Brian Orelli |
Make Money Even When Drugs Fail Biotech growth potential without as much risk can come from innovations that help drugmakers discover new drugs. |
The Motley Fool
December 31, 2009
Brian Orelli |
2010 FDA Decisions to Watch It's a pivotal year for these drugmakers. |
The Motley Fool
December 31, 2009
Brian Orelli |
The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims. |
BusinessWeek
December 30, 2009
Kerry Capell |
Multiple Sclerosis: A Breakthrough Is on the Way A number of improved treatments will be available soon, and Novartis' Fingolimod could lead the way |
The Motley Fool
December 30, 2009
Brian Orelli |
Pfizer Pflubs -- You Expected Otherwise? Bad news, but rather expected. |
The Motley Fool
December 30, 2009
Brian Orelli |
The Best Stocks for 2010: Intuitive Surgical Intuitive Surgical never looks cheap. Then again, good growth stocks usually don't. |
The Motley Fool
December 29, 2009
Brian Orelli |
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. |
The Motley Fool
December 24, 2009
Brian Orelli |
Health-Care Reform: Two-Thirds Finished The U.S. Senate voted this morning to pass the health-care reform bill, moving us closer to capping off the long process that's weighed on health-care and insurance stocks this year. |
| <Older 6111-6120 Newer> Return to current articles. |
